https://doi.org/10.5061/dryad.1g1jwsv43

This dataset contains supplementary data for the above-titled manuscript.

Description of the data and file structure

The supplementary material includes 3 tables and 2 figures, as follows:

• Supplementary Table 1—DXA Body Composition Data Excluding Participant #2*
  • Dual x-ray absorptiometry data results showing the change in key body composition metrics from baseline (pre-low glycemic load diet initiation) to study completion (after 8 weeks of the low glycemic load diet intervention)
  • The +/- values are measures of standard error (SE) across the study group (SE= standard deviation divided by the square root of the number of samples)
  • A p-value of </=0.05 was considered statistically significant
  • Participant #2 was excluded due to a significant change in physical activity level mid-study
  • Weight and body mass index (BMI) were measured in kg and kg/m2, respectively
  • Measures of body composition were measured in grams (gm-- total fat mass, total lean mass, trunk fat mass), body percentage (% fat mass, % trunk fat, or kg/m2 for several key comparissons between body mass and body area (fat mass index, lean mass index, appendicular lean mass index). Appendicular refers to the limbs (arms and legs).
  • Four measures of fat mass showed significant improvement after completion of the low glycemic load diet (total fat mass, % fat mass, trunk fat, % trunk fat)
• Supplementary Table 2—Biochemical Data
  • Comparison of participants' averaged key serum lab results pre- and post-low glycemic load (LGL) diet intervention (8 weeks)
  • Includes inflammatory markers (ESR, erythrocyte sedimentation rate; CRP, C-reactive protein) and hemoglobin A1c. Inflammatory markers are general screening tests for gastrointestinal disease/inflammation, and HbA1c in the primary screening test for diabetes mellitus (diabetes >/= 6.5%; pre-diabetes 5.7-6.4%; normal <5.7%).
  • ESR is measured in millimeters per hour (mm/hr), CRP as miligrams per liter (mg/L), and HbA1c as a percentage of red blood cells that are glycated (%)
  • The +/- values are measures of standard error across the study group (SE= standard deviation divided by the square root of the number of samples)
  • A p-value of </=0.05 was considered statistically significant
  • There was no significant change in serum results during the study
• Supplementary Table 3—Detailed Participant Weight Data
  • Summary of changes in weight throughout the entire study period for each individual
  • Weight data was collected via a study-provided, callibrated home scale and reported on a weekly basis
  • The start weight reflects the value recorded at the baseline visit; the end weight at the last study visit; the lowest weight is the lowest value recorded on weekly home measured data; the absolute change and percent (%) change reflect the comparison between the study start weight and end weight
  • Bolded values reflect individuals whom lost more than 1.7% of their body weight, which was deemed clinically notable based on our pre-study analysis
• Supplemental Figure 1— Diet Tolerability Questionnaire
  • Copy of the unvalidated survery used to assess the low glycemic load diet tolerability at study completion
• Supplemental Figure 2— Study Timeline Diagram
  • Outline of the study timeline for each participant
  • After the baseline visit, participants adhered to their typical diet for 14 days, then transitioned to the low-glycemic load diet for 8 weeks
• Raw Data Excel File
  • Supp Table 1 contains the raw dual x-ray absorptiometry (DXA) data for each participant, comparing values of lean mass and fat mass between baseline (variable 1) and study completion (variable 2)
    • Participants #5 and #6 did not complete baseline or follow up DXA studies due to logistical issues
  • Supple Table 2 contains the raw data of serum values outlined in supplementary Table 2, comparing lab results from baseline and study completion (ESR, erythrocyte sedimentaiton rate; CRP, C-reactive protein; A1c, hemoglobin A1c)
    • Participant #2 did not provide enough sample/serum for all follow up labs to be obtained, therefore we do not have a CRP level for this visit

Sharing/Access information

There are no other available publicly accessible links/means to accessing this data.